Physician profile
Jenna M Ring
NPI 1124463500
$2,257.74
in general payments reported to CMS, 2019-2025
25 companies · $760 in 2025
The $760 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $206 · 2023: $300 · 2024: $516 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $391.27 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $347.15 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $326.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $253.71 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $181.37 | 2023-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.67 | 2024-2025 | Caplyta |
| Lundbeck LLC | $73.46 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $71.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $69.49 | 2021 | |
| Abbvie INC. | $59.18 | 2021-2025 | |
| Amarin Pharma, INC. | $55.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.40 | 2021 | |
| Merck Sharp & Dohme LLC | $47.20 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $33.08 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $25.94 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.81 | 2024 | |
| Axsome Therapeutics, INC. | $21.88 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $21.82 | 2024 | Voquezna |
| Exact Sciences Corporation | $21.53 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $21.40 | 2025 | Watchman Flx |
| Eisai INC. | $20.40 | 2021 | |
| Gilead Sciences, INC. | $19.88 | 2023 | |
| Pfizer INC. | $16.09 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2022 | |
| Edwards Lifesciences Corporation | $14.62 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.